Fernando Holguin
Concepts (627)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 128 | 2025 | 1797 | 13.810 |
Why?
| | Obesity | 36 | 2025 | 3118 | 3.350 |
Why?
| | Anti-Asthmatic Agents | 15 | 2025 | 260 | 3.220 |
Why?
| | Air Pollutants | 19 | 2025 | 406 | 2.580 |
Why?
| | Vehicle Emissions | 11 | 2017 | 57 | 2.140 |
Why?
| | Nitric Oxide | 17 | 2025 | 892 | 1.860 |
Why?
| | Citrulline | 3 | 2023 | 45 | 1.820 |
Why?
| | Lung | 26 | 2025 | 4116 | 1.490 |
Why?
| | Air Pollution | 12 | 2024 | 315 | 1.330 |
Why?
| | Adrenal Cortex Hormones | 20 | 2025 | 484 | 1.290 |
Why?
| | Environmental Exposure | 15 | 2025 | 578 | 1.280 |
Why?
| | Minority Groups | 3 | 2021 | 285 | 1.250 |
Why?
| | Arginine | 5 | 2023 | 264 | 1.250 |
Why?
| | Biological Products | 2 | 2025 | 257 | 1.250 |
Why?
| | Metabolic Syndrome | 4 | 2019 | 361 | 1.160 |
Why?
| | Lung Diseases | 5 | 2021 | 782 | 1.130 |
Why?
| | Humans | 164 | 2026 | 145750 | 1.060 |
Why?
| | September 11 Terrorist Attacks | 2 | 2021 | 31 | 1.040 |
Why?
| | Bronchial Hyperreactivity | 4 | 2025 | 104 | 1.010 |
Why?
| | Patient Selection | 2 | 2021 | 739 | 0.990 |
Why?
| | Particulate Matter | 12 | 2025 | 326 | 0.980 |
Why?
| | Inflammation | 15 | 2025 | 2883 | 0.980 |
Why?
| | Forced Expiratory Volume | 17 | 2026 | 450 | 0.970 |
Why?
| | Severity of Illness Index | 23 | 2025 | 2933 | 0.950 |
Why?
| | Dietary Supplements | 5 | 2019 | 584 | 0.950 |
Why?
| | Respiratory Sounds | 3 | 2021 | 103 | 0.910 |
Why?
| | Adult | 75 | 2025 | 40867 | 0.880 |
Why?
| | Oxidative Stress | 9 | 2024 | 1359 | 0.880 |
Why?
| | Hospitalization | 8 | 2020 | 2460 | 0.880 |
Why?
| | Respiratory Function Tests | 13 | 2026 | 544 | 0.860 |
Why?
| | Bronchodilator Agents | 9 | 2023 | 187 | 0.840 |
Why?
| | Plant Stems | 1 | 2024 | 8 | 0.830 |
Why?
| | Tocopherols | 1 | 2024 | 31 | 0.820 |
Why?
| | Pulmonary Medicine | 3 | 2021 | 78 | 0.810 |
Why?
| | Asteraceae | 1 | 2024 | 20 | 0.810 |
Why?
| | Glucocorticoids | 5 | 2024 | 532 | 0.810 |
Why?
| | Adrenergic beta-Agonists | 3 | 2020 | 92 | 0.780 |
Why?
| | Mucus | 4 | 2025 | 75 | 0.770 |
Why?
| | Nitrogen Dioxide | 5 | 2025 | 45 | 0.750 |
Why?
| | Plant Leaves | 1 | 2024 | 131 | 0.740 |
Why?
| | Aryldialkylphosphatase | 1 | 2022 | 17 | 0.720 |
Why?
| | Fatty Acids, Omega-3 | 4 | 2015 | 143 | 0.700 |
Why?
| | Microalgae | 2 | 2018 | 8 | 0.700 |
Why?
| | Phenotype | 16 | 2025 | 3170 | 0.690 |
Why?
| | Middle Aged | 58 | 2026 | 36297 | 0.690 |
Why?
| | Sleep Medicine Specialty | 1 | 2021 | 10 | 0.690 |
Why?
| | Male | 90 | 2026 | 72992 | 0.690 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 6 | 2022 | 920 | 0.680 |
Why?
| | Gonadal Steroid Hormones | 2 | 2020 | 143 | 0.680 |
Why?
| | Thiazolidinediones | 2 | 2015 | 143 | 0.680 |
Why?
| | Female | 89 | 2026 | 79025 | 0.660 |
Why?
| | Sleep Apnea, Obstructive | 2 | 2022 | 303 | 0.660 |
Why?
| | Transients and Migrants | 2 | 2018 | 27 | 0.640 |
Why?
| | Fluticasone | 5 | 2021 | 53 | 0.640 |
Why?
| | Respiratory Mucosa | 7 | 2025 | 322 | 0.630 |
Why?
| | Heart Rate | 3 | 2013 | 856 | 0.620 |
Why?
| | Administration, Inhalation | 15 | 2024 | 571 | 0.610 |
Why?
| | Hydroxyurea | 1 | 2019 | 34 | 0.610 |
Why?
| | Lipoxygenase Inhibitors | 1 | 2019 | 34 | 0.610 |
Why?
| | Respiratory Tract Diseases | 3 | 2017 | 175 | 0.610 |
Why?
| | Risk Factors | 25 | 2025 | 10916 | 0.600 |
Why?
| | Social Class | 2 | 2021 | 264 | 0.600 |
Why?
| | Hypereosinophilic Syndrome | 1 | 2019 | 8 | 0.590 |
Why?
| | Immunoglobulin E | 7 | 2025 | 315 | 0.590 |
Why?
| | Leptin | 3 | 2011 | 248 | 0.580 |
Why?
| | Carotenoids | 1 | 2019 | 47 | 0.580 |
Why?
| | Stramenopiles | 1 | 2018 | 1 | 0.570 |
Why?
| | Adiponectin | 3 | 2011 | 242 | 0.570 |
Why?
| | Body Mass Index | 14 | 2025 | 2447 | 0.570 |
Why?
| | Biosynthetic Pathways | 1 | 2018 | 24 | 0.570 |
Why?
| | Pulmonary Eosinophilia | 1 | 2018 | 27 | 0.560 |
Why?
| | Age of Onset | 5 | 2018 | 557 | 0.550 |
Why?
| | Young Adult | 27 | 2021 | 14250 | 0.550 |
Why?
| | Bronchoalveolar Lavage Fluid | 10 | 2020 | 638 | 0.530 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2021 | 1751 | 0.520 |
Why?
| | Biomedical Research | 2 | 2021 | 719 | 0.510 |
Why?
| | Pyridones | 1 | 2019 | 209 | 0.500 |
Why?
| | Fluorocarbons | 1 | 2018 | 120 | 0.500 |
Why?
| | Acclimatization | 1 | 2018 | 170 | 0.500 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2018 | 118 | 0.500 |
Why?
| | Thinness | 3 | 2021 | 100 | 0.500 |
Why?
| | Nitrosative Stress | 1 | 2016 | 4 | 0.500 |
Why?
| | United States | 26 | 2025 | 16122 | 0.480 |
Why?
| | Biomarkers | 15 | 2025 | 4302 | 0.480 |
Why?
| | Salmeterol Xinafoate | 3 | 2021 | 20 | 0.480 |
Why?
| | Triglycerides | 1 | 2018 | 520 | 0.480 |
Why?
| | Respiratory Tract Infections | 4 | 2016 | 396 | 0.470 |
Why?
| | Critical Care | 2 | 2021 | 702 | 0.470 |
Why?
| | Adolescent | 36 | 2025 | 22569 | 0.460 |
Why?
| | Dyslipidemias | 1 | 2017 | 184 | 0.460 |
Why?
| | Ozone | 4 | 2025 | 116 | 0.460 |
Why?
| | Aedes | 3 | 2026 | 66 | 0.450 |
Why?
| | Soybean Oil | 2 | 2005 | 15 | 0.450 |
Why?
| | Fish Oils | 2 | 2005 | 27 | 0.450 |
Why?
| | Environmental Monitoring | 6 | 2017 | 347 | 0.450 |
Why?
| | Oxidation-Reduction | 4 | 2018 | 1068 | 0.430 |
Why?
| | Fatty Acids, Omega-6 | 2 | 2015 | 47 | 0.430 |
Why?
| | Epithelial Cells | 8 | 2025 | 1134 | 0.430 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2018 | 373 | 0.420 |
Why?
| | Reproducibility of Results | 3 | 2025 | 3416 | 0.420 |
Why?
| | Inflammation Mediators | 3 | 2014 | 507 | 0.410 |
Why?
| | Exhalation | 2 | 2020 | 29 | 0.410 |
Why?
| | Epigenesis, Genetic | 2 | 2023 | 693 | 0.410 |
Why?
| | Insect Repellents | 2 | 2024 | 7 | 0.400 |
Why?
| | Child | 36 | 2025 | 22738 | 0.400 |
Why?
| | Carbon Monoxide | 1 | 2013 | 82 | 0.390 |
Why?
| | Eczema | 1 | 2014 | 66 | 0.390 |
Why?
| | Aged | 24 | 2026 | 26212 | 0.380 |
Why?
| | Eosinophils | 6 | 2025 | 316 | 0.380 |
Why?
| | Ornithine | 2 | 2023 | 27 | 0.380 |
Why?
| | Inhalation Exposure | 1 | 2013 | 103 | 0.380 |
Why?
| | Morbidity | 3 | 2023 | 322 | 0.380 |
Why?
| | Health Status | 2 | 2024 | 835 | 0.370 |
Why?
| | Life Style | 3 | 2026 | 486 | 0.370 |
Why?
| | Hospital Mortality | 3 | 2020 | 1038 | 0.360 |
Why?
| | Rhinitis | 1 | 2014 | 169 | 0.350 |
Why?
| | Lung Diseases, Obstructive | 1 | 2012 | 43 | 0.350 |
Why?
| | Spirometry | 5 | 2026 | 233 | 0.350 |
Why?
| | Air Pollutants, Occupational | 1 | 2012 | 41 | 0.350 |
Why?
| | Ventricular Function, Right | 1 | 2014 | 297 | 0.340 |
Why?
| | Dust | 1 | 2012 | 92 | 0.340 |
Why?
| | Immunologic Factors | 1 | 2014 | 260 | 0.340 |
Why?
| | Firefighters | 1 | 2012 | 47 | 0.330 |
Why?
| | Prevalence | 7 | 2020 | 2874 | 0.330 |
Why?
| | Bronchoconstriction | 2 | 2010 | 29 | 0.330 |
Why?
| | Exercise Test | 2 | 2025 | 630 | 0.320 |
Why?
| | Comorbidity | 10 | 2023 | 1662 | 0.320 |
Why?
| | Double-Blind Method | 11 | 2019 | 2064 | 0.320 |
Why?
| | Cardiovascular Diseases | 3 | 2020 | 2190 | 0.320 |
Why?
| | Eosinophilia | 3 | 2020 | 224 | 0.310 |
Why?
| | Atherosclerosis | 1 | 2014 | 409 | 0.310 |
Why?
| | Sputum | 6 | 2019 | 302 | 0.310 |
Why?
| | Pediatric Obesity | 1 | 2017 | 638 | 0.310 |
Why?
| | Hypersensitivity | 3 | 2022 | 254 | 0.310 |
Why?
| | Airway Resistance | 1 | 2010 | 38 | 0.310 |
Why?
| | Quality of Life | 8 | 2023 | 3210 | 0.310 |
Why?
| | Air Pollution, Indoor | 3 | 2024 | 171 | 0.300 |
Why?
| | Respiratory Mechanics | 1 | 2010 | 74 | 0.300 |
Why?
| | Alendronate | 2 | 2019 | 14 | 0.300 |
Why?
| | Pneumocystis carinii | 1 | 2009 | 12 | 0.290 |
Why?
| | Heart Ventricles | 1 | 2014 | 756 | 0.290 |
Why?
| | Overweight | 3 | 2024 | 614 | 0.290 |
Why?
| | Pneumonia, Pneumocystis | 1 | 2009 | 34 | 0.290 |
Why?
| | Intensive Care Units | 2 | 2020 | 924 | 0.280 |
Why?
| | Hydrogen Peroxide | 3 | 2022 | 335 | 0.280 |
Why?
| | Antibodies, Antineutrophil Cytoplasmic | 1 | 2008 | 33 | 0.280 |
Why?
| | Cystic Fibrosis | 1 | 2018 | 1163 | 0.280 |
Why?
| | Health Services | 1 | 2009 | 113 | 0.280 |
Why?
| | Child, Preschool | 17 | 2025 | 11866 | 0.270 |
Why?
| | Precision Medicine | 3 | 2021 | 461 | 0.270 |
Why?
| | Vasculitis | 1 | 2008 | 69 | 0.270 |
Why?
| | Mexico | 7 | 2013 | 233 | 0.270 |
Why?
| | Occupational Exposure | 1 | 2012 | 355 | 0.270 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2009 | 130 | 0.270 |
Why?
| | Treatment Outcome | 11 | 2026 | 11793 | 0.270 |
Why?
| | Mucins | 2 | 2025 | 75 | 0.260 |
Why?
| | Th2 Cells | 3 | 2019 | 175 | 0.260 |
Why?
| | Intubation, Intratracheal | 2 | 2020 | 327 | 0.260 |
Why?
| | Multivariate Analysis | 6 | 2018 | 1547 | 0.260 |
Why?
| | Schools | 6 | 2021 | 449 | 0.260 |
Why?
| | Isoprostanes | 1 | 2007 | 15 | 0.260 |
Why?
| | Cross-Sectional Studies | 10 | 2025 | 5921 | 0.260 |
Why?
| | Health Services Accessibility | 3 | 2024 | 1101 | 0.250 |
Why?
| | Bronchi | 3 | 2018 | 263 | 0.250 |
Why?
| | Breath Tests | 4 | 2018 | 77 | 0.250 |
Why?
| | Albuterol | 5 | 2023 | 76 | 0.250 |
Why?
| | Fatty Acids | 2 | 2021 | 457 | 0.250 |
Why?
| | Aged, 80 and over | 7 | 2020 | 8346 | 0.250 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2024 | 992 | 0.250 |
Why?
| | Cytokines | 5 | 2019 | 2069 | 0.250 |
Why?
| | Vital Capacity | 5 | 2026 | 292 | 0.240 |
Why?
| | Disease Progression | 9 | 2025 | 2865 | 0.240 |
Why?
| | Patient Admission | 1 | 2008 | 220 | 0.240 |
Why?
| | Refugees | 2 | 2018 | 83 | 0.240 |
Why?
| | Gene Expression Regulation | 5 | 2025 | 2601 | 0.240 |
Why?
| | Anopheles | 1 | 2026 | 18 | 0.240 |
Why?
| | Animal Feed | 1 | 2026 | 49 | 0.240 |
Why?
| | Interleukin-13 | 4 | 2020 | 146 | 0.230 |
Why?
| | Longitudinal Studies | 6 | 2020 | 2967 | 0.230 |
Why?
| | Logistic Models | 4 | 2020 | 2139 | 0.230 |
Why?
| | Chlamydomonas reinhardtii | 2 | 2015 | 8 | 0.220 |
Why?
| | Societies, Medical | 5 | 2023 | 900 | 0.220 |
Why?
| | Animals | 18 | 2026 | 38100 | 0.220 |
Why?
| | Fucosyltransferases | 1 | 2025 | 33 | 0.220 |
Why?
| | Picornaviridae Infections | 1 | 2025 | 53 | 0.220 |
Why?
| | Cholecalciferol | 2 | 2016 | 61 | 0.210 |
Why?
| | Self Report | 2 | 2019 | 875 | 0.210 |
Why?
| | Autonomic Nervous System | 1 | 2005 | 83 | 0.210 |
Why?
| | Leukocyte Count | 4 | 2020 | 318 | 0.210 |
Why?
| | Resins, Plant | 1 | 2024 | 5 | 0.210 |
Why?
| | Nitrogen | 2 | 2015 | 125 | 0.210 |
Why?
| | Rubber | 1 | 2024 | 8 | 0.210 |
Why?
| | Upper Extremity | 1 | 2025 | 113 | 0.210 |
Why?
| | Sex Factors | 4 | 2018 | 2110 | 0.210 |
Why?
| | Prospective Studies | 9 | 2024 | 8075 | 0.200 |
Why?
| | Microbiota | 3 | 2022 | 730 | 0.200 |
Why?
| | Mexican Americans | 1 | 2004 | 119 | 0.200 |
Why?
| | Lipid Metabolism | 2 | 2018 | 529 | 0.190 |
Why?
| | Oils, Volatile | 1 | 2023 | 5 | 0.190 |
Why?
| | Mitochondrial Diseases | 1 | 2024 | 92 | 0.190 |
Why?
| | Insect Bites and Stings | 1 | 2023 | 13 | 0.190 |
Why?
| | Arabidopsis | 1 | 2024 | 94 | 0.190 |
Why?
| | Ixodes | 1 | 2023 | 12 | 0.190 |
Why?
| | Respiration, Artificial | 3 | 2020 | 714 | 0.190 |
Why?
| | Vitamin D Deficiency | 2 | 2016 | 190 | 0.190 |
Why?
| | Housing | 1 | 2024 | 142 | 0.190 |
Why?
| | Respiratory System | 3 | 2020 | 150 | 0.190 |
Why?
| | Diet | 3 | 2026 | 1278 | 0.190 |
Why?
| | Proof of Concept Study | 2 | 2019 | 89 | 0.190 |
Why?
| | Reflex | 1 | 2023 | 70 | 0.190 |
Why?
| | Metformin | 1 | 2026 | 329 | 0.180 |
Why?
| | Nitric Oxide Synthase Type II | 2 | 2019 | 162 | 0.180 |
Why?
| | Vagus Nerve | 1 | 2023 | 92 | 0.180 |
Why?
| | Nutrition Surveys | 3 | 2018 | 279 | 0.180 |
Why?
| | Smoking | 3 | 2020 | 1477 | 0.180 |
Why?
| | Quercetin | 1 | 2022 | 19 | 0.180 |
Why?
| | Incidence | 5 | 2020 | 2933 | 0.180 |
Why?
| | Pilot Projects | 2 | 2019 | 1897 | 0.180 |
Why?
| | Hypersensitivity, Immediate | 2 | 2016 | 41 | 0.180 |
Why?
| | Antioxidants | 4 | 2016 | 550 | 0.180 |
Why?
| | Neurodegenerative Diseases | 1 | 2024 | 143 | 0.170 |
Why?
| | Geography | 2 | 2021 | 187 | 0.170 |
Why?
| | Nitro Compounds | 1 | 2021 | 8 | 0.170 |
Why?
| | Oleic Acids | 1 | 2021 | 12 | 0.170 |
Why?
| | Omalizumab | 1 | 2021 | 43 | 0.170 |
Why?
| | Residence Characteristics | 1 | 2004 | 375 | 0.170 |
Why?
| | Waiting Lists | 1 | 2023 | 266 | 0.170 |
Why?
| | Respiratory Insufficiency | 2 | 2020 | 326 | 0.170 |
Why?
| | Pharmacogenomic Testing | 1 | 2021 | 63 | 0.170 |
Why?
| | Arginase | 1 | 2021 | 26 | 0.170 |
Why?
| | Public Policy | 1 | 2021 | 80 | 0.160 |
Why?
| | Signal Transduction | 5 | 2020 | 5223 | 0.160 |
Why?
| | Automobiles | 3 | 2011 | 18 | 0.160 |
Why?
| | Symptom Flare Up | 1 | 2020 | 37 | 0.160 |
Why?
| | Fatty Acids, Unsaturated | 2 | 2018 | 96 | 0.160 |
Why?
| | Patient Advocacy | 1 | 2021 | 73 | 0.160 |
Why?
| | Disulfides | 1 | 2021 | 94 | 0.160 |
Why?
| | Public Health | 3 | 2018 | 574 | 0.160 |
Why?
| | Stakeholder Participation | 1 | 2021 | 85 | 0.160 |
Why?
| | Socioeconomic Factors | 4 | 2018 | 1327 | 0.160 |
Why?
| | Health Policy | 2 | 2021 | 400 | 0.160 |
Why?
| | Geographic Mapping | 1 | 2020 | 26 | 0.160 |
Why?
| | Geographic Information Systems | 1 | 2020 | 45 | 0.160 |
Why?
| | Mucin 5AC | 3 | 2025 | 71 | 0.160 |
Why?
| | Bile Acids and Salts | 1 | 2021 | 163 | 0.160 |
Why?
| | Self-Management | 1 | 2023 | 202 | 0.160 |
Why?
| | Soot | 3 | 2015 | 23 | 0.160 |
Why?
| | Chemotaxis | 1 | 2020 | 122 | 0.160 |
Why?
| | Case-Control Studies | 6 | 2020 | 3634 | 0.160 |
Why?
| | Hypoglycemic Agents | 2 | 2026 | 1399 | 0.160 |
Why?
| | Lung Transplantation | 1 | 2023 | 332 | 0.150 |
Why?
| | Neutrophils | 3 | 2020 | 1125 | 0.150 |
Why?
| | Dyspnea | 1 | 2022 | 250 | 0.150 |
Why?
| | Puberty | 2 | 2018 | 137 | 0.150 |
Why?
| | Muscarinic Antagonists | 1 | 2019 | 30 | 0.150 |
Why?
| | Frailty | 1 | 2023 | 205 | 0.150 |
Why?
| | Gene Expression | 4 | 2018 | 1478 | 0.150 |
Why?
| | Poverty | 1 | 2024 | 528 | 0.150 |
Why?
| | Age Factors | 5 | 2018 | 3346 | 0.150 |
Why?
| | Th1 Cells | 2 | 2017 | 139 | 0.150 |
Why?
| | Noninvasive Ventilation | 1 | 2020 | 62 | 0.150 |
Why?
| | Uncertainty | 1 | 2020 | 146 | 0.150 |
Why?
| | Nitric Oxide Synthase | 2 | 2019 | 234 | 0.150 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 1 | 2019 | 26 | 0.150 |
Why?
| | Mometasone Furoate | 1 | 2019 | 3 | 0.150 |
Why?
| | Tiotropium Bromide | 1 | 2019 | 5 | 0.150 |
Why?
| | Trust | 1 | 2021 | 158 | 0.150 |
Why?
| | Tissue and Organ Procurement | 1 | 2023 | 343 | 0.150 |
Why?
| | Mucin-4 | 1 | 2019 | 3 | 0.150 |
Why?
| | Sialyltransferases | 1 | 2019 | 13 | 0.150 |
Why?
| | 2-Hydroxypropyl-beta-cyclodextrin | 1 | 2018 | 7 | 0.140 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2019 | 36 | 0.140 |
Why?
| | Saline Waters | 1 | 2018 | 1 | 0.140 |
Why?
| | Interleukins | 1 | 2020 | 248 | 0.140 |
Why?
| | Gastroesophageal Reflux | 1 | 2021 | 237 | 0.140 |
Why?
| | Immunity | 2 | 2022 | 140 | 0.140 |
Why?
| | Dioxanes | 1 | 2018 | 11 | 0.140 |
Why?
| | DNA, Mitochondrial | 1 | 2020 | 211 | 0.140 |
Why?
| | Cities | 4 | 2013 | 139 | 0.140 |
Why?
| | Immunoglobulin Fragments | 1 | 2018 | 11 | 0.140 |
Why?
| | Lung Neoplasms | 2 | 2023 | 2667 | 0.140 |
Why?
| | Diagnosis, Differential | 2 | 2020 | 1512 | 0.140 |
Why?
| | Oxidoreductases | 1 | 2019 | 91 | 0.140 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2020 | 194 | 0.140 |
Why?
| | Moraxella | 1 | 2018 | 4 | 0.140 |
Why?
| | Porosity | 1 | 2018 | 94 | 0.140 |
Why?
| | Airway Remodeling | 2 | 2016 | 63 | 0.140 |
Why?
| | DNA Methylation | 1 | 2023 | 690 | 0.140 |
Why?
| | Cross-Over Studies | 4 | 2025 | 610 | 0.140 |
Why?
| | Adsorption | 1 | 2018 | 153 | 0.140 |
Why?
| | Water | 2 | 2018 | 447 | 0.140 |
Why?
| | Weight Loss | 2 | 2023 | 859 | 0.130 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2026 | 2602 | 0.130 |
Why?
| | Interferon-gamma | 2 | 2025 | 784 | 0.130 |
Why?
| | Corynebacterium | 1 | 2018 | 50 | 0.130 |
Why?
| | Metabolome | 2 | 2018 | 391 | 0.130 |
Why?
| | Gastrointestinal Microbiome | 1 | 2025 | 768 | 0.130 |
Why?
| | Silicon Dioxide | 1 | 2018 | 119 | 0.130 |
Why?
| | Volatile Organic Compounds | 1 | 2017 | 47 | 0.130 |
Why?
| | Adaptive Clinical Trials as Topic | 3 | 2021 | 24 | 0.130 |
Why?
| | Cold Temperature | 1 | 2018 | 206 | 0.130 |
Why?
| | Proportional Hazards Models | 2 | 2019 | 1330 | 0.130 |
Why?
| | Surveys and Questionnaires | 6 | 2023 | 6084 | 0.130 |
Why?
| | Emergency Service, Hospital | 2 | 2025 | 2383 | 0.120 |
Why?
| | Retrospective Studies | 8 | 2023 | 17322 | 0.120 |
Why?
| | Lung Diseases, Interstitial | 1 | 2023 | 664 | 0.120 |
Why?
| | Mice | 9 | 2025 | 18357 | 0.120 |
Why?
| | Vocal Cord Dysfunction | 1 | 2016 | 9 | 0.120 |
Why?
| | Leukotriene Antagonists | 1 | 2016 | 24 | 0.120 |
Why?
| | Voice Quality | 1 | 2016 | 23 | 0.120 |
Why?
| | Health Services Needs and Demand | 1 | 2018 | 280 | 0.120 |
Why?
| | Water Purification | 1 | 2018 | 156 | 0.120 |
Why?
| | RNA, Messenger | 3 | 2020 | 2805 | 0.120 |
Why?
| | Functional Food | 1 | 2016 | 4 | 0.120 |
Why?
| | Food Quality | 1 | 2016 | 9 | 0.120 |
Why?
| | Drug Resistance | 1 | 2017 | 145 | 0.120 |
Why?
| | Chemokines, CC | 2 | 2014 | 33 | 0.120 |
Why?
| | Pigments, Biological | 1 | 2016 | 17 | 0.120 |
Why?
| | Mice, Inbred C57BL | 5 | 2025 | 5992 | 0.120 |
Why?
| | Forced Expiratory Flow Rates | 1 | 2015 | 10 | 0.120 |
Why?
| | Crops, Agricultural | 1 | 2016 | 30 | 0.120 |
Why?
| | Quinolones | 1 | 2018 | 204 | 0.120 |
Why?
| | Vitamins | 2 | 2015 | 184 | 0.120 |
Why?
| | Bronchoconstrictor Agents | 1 | 2015 | 14 | 0.120 |
Why?
| | Zea mays | 1 | 2016 | 44 | 0.120 |
Why?
| | Income | 1 | 2017 | 203 | 0.120 |
Why?
| | Vermont | 1 | 2015 | 13 | 0.120 |
Why?
| | Sleep Apnea Syndromes | 1 | 2017 | 98 | 0.120 |
Why?
| | Anthocyanins | 1 | 2016 | 28 | 0.120 |
Why?
| | Aminophenols | 1 | 2018 | 203 | 0.120 |
Why?
| | Ibuprofen | 1 | 2016 | 87 | 0.120 |
Why?
| | Methacholine Chloride | 1 | 2015 | 51 | 0.120 |
Why?
| | Bronchial Provocation Tests | 1 | 2015 | 47 | 0.120 |
Why?
| | Preventive Medicine | 1 | 2016 | 39 | 0.110 |
Why?
| | Antigens, CD | 1 | 2019 | 558 | 0.110 |
Why?
| | Secretory Leukocyte Peptidase Inhibitor | 1 | 2015 | 6 | 0.110 |
Why?
| | Seeds | 1 | 2016 | 69 | 0.110 |
Why?
| | Disease Management | 1 | 2019 | 653 | 0.110 |
Why?
| | Blood Platelets | 1 | 2019 | 379 | 0.110 |
Why?
| | Health Surveys | 2 | 2009 | 520 | 0.110 |
Why?
| | Homocysteine | 1 | 2015 | 152 | 0.110 |
Why?
| | Hydroxyprostaglandin Dehydrogenases | 1 | 2015 | 3 | 0.110 |
Why?
| | Bariatric Surgery | 1 | 2019 | 253 | 0.110 |
Why?
| | Transportation | 1 | 2015 | 57 | 0.110 |
Why?
| | Azithromycin | 1 | 2015 | 101 | 0.110 |
Why?
| | Healthcare Disparities | 2 | 2023 | 736 | 0.110 |
Why?
| | Interleukin-27 | 1 | 2014 | 13 | 0.110 |
Why?
| | Body Weight | 1 | 2019 | 972 | 0.110 |
Why?
| | Fibrinogen | 1 | 2015 | 180 | 0.110 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2015 | 154 | 0.110 |
Why?
| | Tomography, X-Ray Computed | 3 | 2021 | 2770 | 0.100 |
Why?
| | Pennsylvania | 4 | 2016 | 138 | 0.100 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2020 | 923 | 0.100 |
Why?
| | Pregnenediones | 1 | 2014 | 15 | 0.100 |
Why?
| | Secondary Prevention | 1 | 2015 | 251 | 0.100 |
Why?
| | Photosynthesis | 1 | 2014 | 99 | 0.100 |
Why?
| | Interleukin-6 | 2 | 2016 | 779 | 0.100 |
Why?
| | Health Status Disparities | 1 | 2017 | 321 | 0.100 |
Why?
| | Acetaminophen | 1 | 2016 | 267 | 0.100 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2016 | 196 | 0.100 |
Why?
| | Cells, Cultured | 5 | 2020 | 4151 | 0.100 |
Why?
| | C-Reactive Protein | 1 | 2015 | 423 | 0.100 |
Why?
| | Linear Models | 4 | 2018 | 849 | 0.100 |
Why?
| | Receptors, Prostaglandin | 1 | 2013 | 21 | 0.100 |
Why?
| | Cohort Studies | 8 | 2020 | 6032 | 0.100 |
Why?
| | Prostaglandin D2 | 1 | 2013 | 21 | 0.100 |
Why?
| | Nutritional Status | 1 | 2015 | 353 | 0.100 |
Why?
| | Odds Ratio | 1 | 2015 | 1083 | 0.090 |
Why?
| | Lipids | 2 | 2015 | 707 | 0.090 |
Why?
| | Metallurgy | 1 | 2012 | 9 | 0.090 |
Why?
| | Chemokine CCL24 | 1 | 2012 | 11 | 0.090 |
Why?
| | Dinoprost | 2 | 2009 | 51 | 0.090 |
Why?
| | Sleep Wake Disorders | 1 | 2017 | 314 | 0.090 |
Why?
| | Texas | 4 | 2017 | 273 | 0.090 |
Why?
| | Gene Regulatory Networks | 1 | 2015 | 319 | 0.090 |
Why?
| | Time Factors | 2 | 2015 | 7133 | 0.090 |
Why?
| | Macrophages, Alveolar | 3 | 2015 | 373 | 0.090 |
Why?
| | Brazil | 2 | 2023 | 179 | 0.090 |
Why?
| | Particle Size | 3 | 2011 | 381 | 0.090 |
Why?
| | Disease Models, Animal | 4 | 2025 | 4569 | 0.090 |
Why?
| | Mucin-5B | 2 | 2025 | 234 | 0.090 |
Why?
| | Diet, High-Fat | 2 | 2025 | 266 | 0.090 |
Why?
| | Mice, Inbred BALB C | 3 | 2021 | 1261 | 0.090 |
Why?
| | Receptors, Immunologic | 1 | 2013 | 209 | 0.090 |
Why?
| | Weight Gain | 1 | 2015 | 561 | 0.090 |
Why?
| | Gene Expression Profiling | 1 | 2018 | 1777 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2019 | 2028 | 0.080 |
Why?
| | Leukotriene E4 | 1 | 2011 | 24 | 0.080 |
Why?
| | Cell Differentiation | 1 | 2019 | 2051 | 0.080 |
Why?
| | Research Design | 3 | 2021 | 1139 | 0.080 |
Why?
| | Registries | 1 | 2019 | 2410 | 0.080 |
Why?
| | Glutathione Transferase | 2 | 2009 | 92 | 0.080 |
Why?
| | Functional Residual Capacity | 1 | 2010 | 7 | 0.080 |
Why?
| | Mental Health | 1 | 2017 | 796 | 0.080 |
Why?
| | Inhalation | 1 | 2010 | 29 | 0.080 |
Why?
| | Alabama | 1 | 2009 | 32 | 0.070 |
Why?
| | Nitrites | 1 | 2009 | 88 | 0.070 |
Why?
| | Illinois | 1 | 2009 | 49 | 0.070 |
Why?
| | Adipokines | 1 | 2009 | 57 | 0.070 |
Why?
| | Mice, Knockout | 3 | 2025 | 3130 | 0.070 |
Why?
| | Nitrates | 1 | 2009 | 96 | 0.070 |
Why?
| | Insulin Resistance | 1 | 2017 | 1244 | 0.070 |
Why?
| | Tyrosine | 1 | 2009 | 217 | 0.070 |
Why?
| | Plasmapheresis | 1 | 2008 | 24 | 0.070 |
Why?
| | Gases | 1 | 2009 | 46 | 0.070 |
Why?
| | Chlorine | 1 | 2009 | 59 | 0.070 |
Why?
| | Mice, Obese | 1 | 2007 | 68 | 0.070 |
Why?
| | California | 1 | 2009 | 473 | 0.070 |
Why?
| | Depression | 2 | 2016 | 1557 | 0.060 |
Why?
| | Mutation | 1 | 2018 | 4090 | 0.060 |
Why?
| | Pneumonia | 2 | 2020 | 636 | 0.060 |
Why?
| | Health Care Surveys | 1 | 2009 | 536 | 0.060 |
Why?
| | Employer Health Costs | 1 | 2006 | 4 | 0.060 |
Why?
| | Medication Adherence | 2 | 2023 | 540 | 0.060 |
Why?
| | Glutathione | 1 | 2009 | 370 | 0.060 |
Why?
| | Anti-Retroviral Agents | 1 | 2009 | 251 | 0.060 |
Why?
| | PPAR gamma | 1 | 2007 | 182 | 0.060 |
Why?
| | Phagocytosis | 1 | 2008 | 296 | 0.060 |
Why?
| | Magnetic Resonance Imaging | 1 | 2019 | 3915 | 0.060 |
Why?
| | Clinical Protocols | 2 | 2021 | 280 | 0.060 |
Why?
| | Protein Isoforms | 2 | 2019 | 399 | 0.060 |
Why?
| | Blood | 1 | 2026 | 107 | 0.060 |
Why?
| | Palmitic Acid | 1 | 2025 | 40 | 0.060 |
Why?
| | Bronchoscopy | 3 | 2012 | 227 | 0.060 |
Why?
| | Coronary Disease | 1 | 2008 | 382 | 0.060 |
Why?
| | Urban Health | 1 | 2005 | 96 | 0.060 |
Why?
| | Acute Lung Injury | 1 | 2009 | 307 | 0.060 |
Why?
| | Interviews as Topic | 1 | 2009 | 911 | 0.060 |
Why?
| | RNA, Ribosomal, 16S | 2 | 2018 | 508 | 0.060 |
Why?
| | Rhinovirus | 1 | 2025 | 60 | 0.060 |
Why?
| | Blood Transfusion | 1 | 2008 | 409 | 0.050 |
Why?
| | Health Expenditures | 1 | 2006 | 194 | 0.050 |
Why?
| | Biopsy | 1 | 2008 | 1082 | 0.050 |
Why?
| | Child Day Care Centers | 1 | 2005 | 44 | 0.050 |
Why?
| | Anti-Bacterial Agents | 1 | 2015 | 1925 | 0.050 |
Why?
| | Homeostasis | 1 | 2009 | 644 | 0.050 |
Why?
| | Fats | 1 | 2024 | 13 | 0.050 |
Why?
| | Glycosylation | 1 | 2025 | 173 | 0.050 |
Why?
| | Renal Dialysis | 1 | 2008 | 466 | 0.050 |
Why?
| | Infant | 5 | 2018 | 10089 | 0.050 |
Why?
| | Interleukin-5 | 1 | 2024 | 39 | 0.050 |
Why?
| | Cost of Illness | 1 | 2006 | 324 | 0.050 |
Why?
| | Up-Regulation | 2 | 2020 | 848 | 0.050 |
Why?
| | Survival Rate | 1 | 2009 | 2094 | 0.050 |
Why?
| | Bronchoalveolar Lavage | 2 | 2015 | 89 | 0.050 |
Why?
| | Chemokine CCL26 | 2 | 2014 | 10 | 0.050 |
Why?
| | Hormones | 1 | 2024 | 135 | 0.050 |
Why?
| | Myocardial Ischemia | 1 | 2005 | 285 | 0.050 |
Why?
| | Cattle | 1 | 2026 | 946 | 0.050 |
Why?
| | Nursing Homes | 1 | 2005 | 174 | 0.050 |
Why?
| | Glycolysis | 1 | 2025 | 340 | 0.050 |
Why?
| | Prognosis | 2 | 2010 | 4329 | 0.050 |
Why?
| | Epigenomics | 1 | 2023 | 117 | 0.050 |
Why?
| | National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2022 | 25 | 0.050 |
Why?
| | Recurrence | 2 | 2016 | 1139 | 0.050 |
Why?
| | Tobacco Smoke Pollution | 1 | 2005 | 227 | 0.050 |
Why?
| | Hand Strength | 1 | 2023 | 144 | 0.050 |
Why?
| | Oxygen Consumption | 1 | 2025 | 719 | 0.050 |
Why?
| | Feces | 1 | 2025 | 496 | 0.050 |
Why?
| | Americas | 1 | 2022 | 27 | 0.050 |
Why?
| | Statistics, Nonparametric | 2 | 2013 | 428 | 0.040 |
Why?
| | Biology | 1 | 2023 | 89 | 0.040 |
Why?
| | Chi-Square Distribution | 2 | 2017 | 528 | 0.040 |
Why?
| | Latin America | 1 | 2022 | 96 | 0.040 |
Why?
| | Glycocholic Acid | 1 | 2021 | 2 | 0.040 |
Why?
| | Antigens, Dermatophagoides | 1 | 2021 | 10 | 0.040 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2021 | 75 | 0.040 |
Why?
| | Ursodeoxycholic Acid | 1 | 2021 | 17 | 0.040 |
Why?
| | Respiratory Hypersensitivity | 1 | 2021 | 65 | 0.040 |
Why?
| | Expectorants | 1 | 2021 | 23 | 0.040 |
Why?
| | Critical Care Outcomes | 1 | 2020 | 11 | 0.040 |
Why?
| | Status Asthmaticus | 1 | 2020 | 13 | 0.040 |
Why?
| | Molecular Targeted Therapy | 1 | 2024 | 440 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2024 | 611 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2025 | 1115 | 0.040 |
Why?
| | Dermatitis, Atopic | 1 | 2024 | 322 | 0.040 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2021 | 196 | 0.040 |
Why?
| | International Cooperation | 2 | 2011 | 197 | 0.040 |
Why?
| | HIV Infections | 1 | 2016 | 3195 | 0.040 |
Why?
| | Canada | 1 | 2022 | 432 | 0.040 |
Why?
| | Transcriptome | 2 | 2019 | 1043 | 0.040 |
Why?
| | New York City | 1 | 2020 | 84 | 0.040 |
Why?
| | Censuses | 1 | 2020 | 33 | 0.040 |
Why?
| | Advisory Committees | 1 | 2021 | 229 | 0.040 |
Why?
| | Altitude | 2 | 2016 | 463 | 0.040 |
Why?
| | Feeding Behavior | 1 | 2026 | 691 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2024 | 674 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2020 | 172 | 0.040 |
Why?
| | Research | 1 | 2023 | 431 | 0.040 |
Why?
| | Exercise Tolerance | 1 | 2022 | 283 | 0.040 |
Why?
| | Indians, North American | 1 | 2024 | 598 | 0.040 |
Why?
| | Trichloroethanes | 1 | 2018 | 1 | 0.040 |
Why?
| | Trichloroethylene | 1 | 2018 | 8 | 0.040 |
Why?
| | Behavioral Risk Factor Surveillance System | 1 | 2019 | 57 | 0.040 |
Why?
| | Glycoproteins | 1 | 2021 | 354 | 0.040 |
Why?
| | Stroke | 1 | 2008 | 1271 | 0.040 |
Why?
| | Patient Discharge | 1 | 2005 | 995 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2021 | 1044 | 0.040 |
Why?
| | Groundwater | 1 | 2018 | 40 | 0.030 |
Why?
| | Peak Expiratory Flow Rate | 1 | 2018 | 25 | 0.030 |
Why?
| | Guidelines as Topic | 1 | 2020 | 268 | 0.030 |
Why?
| | Drug Combinations | 1 | 2019 | 396 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 334 | 0.030 |
Why?
| | Mouth Mucosa | 1 | 2018 | 85 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2007 | 2399 | 0.030 |
Why?
| | Growth | 1 | 2018 | 49 | 0.030 |
Why?
| | Epithelium | 1 | 2019 | 311 | 0.030 |
Why?
| | Nose | 1 | 2018 | 67 | 0.030 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2019 | 252 | 0.030 |
Why?
| | Pentanes | 1 | 2017 | 8 | 0.030 |
Why?
| | Cyclohexenes | 1 | 2017 | 4 | 0.030 |
Why?
| | Chlorobenzenes | 1 | 2017 | 18 | 0.030 |
Why?
| | Toluene | 1 | 2017 | 12 | 0.030 |
Why?
| | Xylenes | 1 | 2017 | 8 | 0.030 |
Why?
| | Benzene | 1 | 2017 | 18 | 0.030 |
Why?
| | Terpenes | 1 | 2017 | 24 | 0.030 |
Why?
| | Oils | 1 | 2017 | 22 | 0.030 |
Why?
| | Allergens | 1 | 2020 | 386 | 0.030 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 1 | 2017 | 103 | 0.030 |
Why?
| | Biomass | 1 | 2017 | 96 | 0.030 |
Why?
| | Discriminant Analysis | 1 | 2016 | 35 | 0.030 |
Why?
| | Genome-Wide Association Study | 1 | 2023 | 1430 | 0.030 |
Why?
| | Crop Production | 1 | 2016 | 1 | 0.030 |
Why?
| | Communication | 1 | 2023 | 976 | 0.030 |
Why?
| | Early Detection of Cancer | 1 | 2021 | 486 | 0.030 |
Why?
| | Succinates | 1 | 2016 | 25 | 0.030 |
Why?
| | Plant Breeding | 1 | 2016 | 20 | 0.030 |
Why?
| | Southwestern United States | 1 | 2016 | 93 | 0.030 |
Why?
| | Wound Healing | 1 | 2019 | 355 | 0.030 |
Why?
| | Sex Distribution | 1 | 2017 | 388 | 0.030 |
Why?
| | Glucosides | 1 | 2016 | 56 | 0.030 |
Why?
| | Maximal Midexpiratory Flow Rate | 1 | 2015 | 5 | 0.030 |
Why?
| | Receptors, Interleukin-17 | 1 | 2015 | 6 | 0.030 |
Why?
| | RNA, Bacterial | 1 | 2016 | 182 | 0.030 |
Why?
| | Algal Proteins | 1 | 2015 | 4 | 0.030 |
Why?
| | Vaccination | 1 | 2024 | 1428 | 0.030 |
Why?
| | Principal Component Analysis | 1 | 2016 | 194 | 0.030 |
Why?
| | Hospital Costs | 1 | 2016 | 125 | 0.030 |
Why?
| | Water Pollutants, Chemical | 1 | 2018 | 227 | 0.030 |
Why?
| | Kinetics | 1 | 2018 | 1568 | 0.030 |
Why?
| | Industry | 1 | 2015 | 42 | 0.030 |
Why?
| | Stress, Psychological | 1 | 2024 | 1149 | 0.030 |
Why?
| | Patient Outcome Assessment | 1 | 2016 | 130 | 0.030 |
Why?
| | Photosystem I Protein Complex | 1 | 2014 | 2 | 0.030 |
Why?
| | Chlorophyll | 1 | 2014 | 15 | 0.030 |
Why?
| | Proton-Motive Force | 1 | 2014 | 8 | 0.030 |
Why?
| | Thylakoids | 1 | 2014 | 6 | 0.030 |
Why?
| | Disease Susceptibility | 1 | 2017 | 344 | 0.030 |
Why?
| | Hydroxylation | 1 | 2015 | 47 | 0.030 |
Why?
| | Carbon Cycle | 1 | 2014 | 13 | 0.030 |
Why?
| | Starch | 1 | 2014 | 22 | 0.030 |
Why?
| | Species Specificity | 1 | 2016 | 546 | 0.030 |
Why?
| | Fever | 1 | 2016 | 319 | 0.030 |
Why?
| | Disability Evaluation | 1 | 2016 | 311 | 0.030 |
Why?
| | RNA Stability | 1 | 2015 | 107 | 0.030 |
Why?
| | Gene Expression Regulation, Plant | 1 | 2014 | 54 | 0.030 |
Why?
| | Chemokine CXCL9 | 1 | 2014 | 38 | 0.030 |
Why?
| | Interleukin-17 | 1 | 2015 | 120 | 0.030 |
Why?
| | STAT Transcription Factors | 1 | 2014 | 25 | 0.030 |
Why?
| | Exons | 1 | 2015 | 364 | 0.030 |
Why?
| | Fluorescence | 1 | 2014 | 159 | 0.030 |
Why?
| | Drug Resistance, Bacterial | 1 | 2015 | 185 | 0.030 |
Why?
| | Carbon Isotopes | 1 | 2014 | 143 | 0.030 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2023 | 1419 | 0.030 |
Why?
| | Docosahexaenoic Acids | 1 | 2015 | 88 | 0.030 |
Why?
| | Geriatric Assessment | 1 | 2016 | 240 | 0.030 |
Why?
| | Plant Proteins | 1 | 2014 | 111 | 0.030 |
Why?
| | Sepsis | 1 | 2020 | 664 | 0.030 |
Why?
| | Critical Illness | 1 | 2020 | 900 | 0.030 |
Why?
| | Substrate Specificity | 1 | 2015 | 387 | 0.030 |
Why?
| | Temperature | 1 | 2017 | 633 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 971 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2015 | 782 | 0.020 |
Why?
| | Colorado | 1 | 2024 | 4556 | 0.020 |
Why?
| | Cell Line | 1 | 2019 | 2823 | 0.020 |
Why?
| | Risk | 1 | 2016 | 923 | 0.020 |
Why?
| | Acute Disease | 1 | 2016 | 1036 | 0.020 |
Why?
| | Lipocalins | 1 | 2013 | 35 | 0.020 |
Why?
| | Treatment Failure | 1 | 2014 | 360 | 0.020 |
Why?
| | RNA Interference | 1 | 2015 | 475 | 0.020 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2013 | 65 | 0.020 |
Why?
| | Steel | 1 | 2012 | 6 | 0.020 |
Why?
| | Meteorological Concepts | 1 | 2012 | 6 | 0.020 |
Why?
| | Chemokine CCL11 | 1 | 2012 | 25 | 0.020 |
Why?
| | Genome | 1 | 2015 | 305 | 0.020 |
Why?
| | Spatio-Temporal Analysis | 1 | 2012 | 34 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 979 | 0.020 |
Why?
| | Liver | 1 | 2021 | 1899 | 0.020 |
Why?
| | Down-Regulation | 1 | 2014 | 618 | 0.020 |
Why?
| | Heart Failure | 1 | 2005 | 2326 | 0.020 |
Why?
| | Exercise | 1 | 2024 | 2203 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2012 | 337 | 0.020 |
Why?
| | Administration, Oral | 1 | 2014 | 867 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2015 | 858 | 0.020 |
Why?
| | Epidemiological Monitoring | 1 | 2011 | 70 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2016 | 2123 | 0.020 |
Why?
| | Bacteria | 1 | 2016 | 766 | 0.020 |
Why?
| | Risk Assessment | 1 | 2020 | 3752 | 0.020 |
Why?
| | Pain | 1 | 2016 | 791 | 0.020 |
Why?
| | Patient Acceptance of Health Care | 1 | 2017 | 883 | 0.020 |
Why?
| | Proteome | 1 | 2015 | 514 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 849 | 0.020 |
Why?
| | Seasons | 1 | 2012 | 538 | 0.020 |
Why?
| | Oxygen | 1 | 2014 | 981 | 0.020 |
Why?
| | Chemical Hazard Release | 1 | 2009 | 1 | 0.020 |
Why?
| | Chemokines | 1 | 2010 | 217 | 0.020 |
Why?
| | Railroads | 1 | 2009 | 6 | 0.020 |
Why?
| | Glutathione Reductase | 1 | 2009 | 24 | 0.020 |
Why?
| | Malondialdehyde | 1 | 2009 | 31 | 0.020 |
Why?
| | Hazardous Substances | 1 | 2009 | 16 | 0.020 |
Why?
| | South Carolina | 1 | 2009 | 47 | 0.020 |
Why?
| | Glutathione Peroxidase | 1 | 2009 | 41 | 0.020 |
Why?
| | Anxiety | 1 | 2016 | 1122 | 0.020 |
Why?
| | Voice Disorders | 1 | 2009 | 23 | 0.020 |
Why?
| | Nasal Lavage Fluid | 1 | 2008 | 15 | 0.020 |
Why?
| | Energy Metabolism | 1 | 2014 | 935 | 0.020 |
Why?
| | Models, Theoretical | 1 | 2011 | 560 | 0.020 |
Why?
| | Cough | 1 | 2009 | 124 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2016 | 5428 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2015 | 3551 | 0.020 |
Why?
| | Immunity, Innate | 1 | 2013 | 835 | 0.020 |
Why?
| | Office Visits | 1 | 2006 | 93 | 0.020 |
Why?
| | Interleukin-10 | 1 | 2008 | 310 | 0.010 |
Why?
| | Drug Prescriptions | 1 | 2006 | 288 | 0.010 |
Why?
| | Ambulatory Care | 1 | 2006 | 610 | 0.010 |
Why?
| | Algorithms | 1 | 2008 | 1850 | 0.010 |
Why?
| | Apoptosis | 1 | 2008 | 2443 | 0.010 |
Why?
|
|
Holguin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|